Hillsdale Investment Management Inc. Immunovant, Inc. Call Options Transaction History
Hillsdale Investment Management Inc.
- $1.13 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMVT
# of Institutions
238Shares Held
62.9MCall Options Held
1.46MPut Options Held
546K-
Vanguard Group Inc Valley Forge, PA6.48MShares$178 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.48MShares$123 Million0.0% of portfolio
-
State Street Corp Boston, MA3.64MShares$100 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.96MShares$81.5 Million2.01% of portfolio
-
Armistice Capital, LLC New York, NY2.16MShares$59.5 Million0.95% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...